Form 4: Dexcom CEO Kevin Sayer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Dexcom's CEO, Kevin Sayer, sold 32,498 shares of common stock on March 12, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On March 12, 2025, Kevin R. Sayer, the Chairman, CEO, and President of Dexcom Inc., sold 32,498 shares of Dexcom's common stock.
- The sale was executed at a price of $70.3801 per share.
- This transaction was to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- Following the transaction, Sayer directly owns 372,029 shares of Dexcom.
- This number includes 138,091 unvested restricted stock units granted on March 8, 2025, March 8, 2024, and March 9, 2023, which vest through March 8, 2028, March 8, 2027, and March 8, 2026, respectively.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction (sale of shares to cover taxes on vested RSUs) by the CEO. It's neutral to slightly positive as it indicates the CEO is receiving and vesting equity compensation.
Industry Context
Executive stock sales to cover tax obligations upon RSU vesting are a common practice and don't necessarily indicate a negative outlook on the company.
Comparison to Industry Standards
- Executive compensation packages often include RSUs, which vest over time and are subject to income tax.
- The 'sell to cover' strategy is a standard method for executives to manage tax liabilities associated with RSU vesting, similar to practices observed at companies like Medtronic and Abbott.
Stakeholder Impact
- The sale may have a minor, temporary impact on shareholders due to the increased supply of shares in the market.
- The transaction has no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 03/09/2023 | Date of grant for 18,140 restricted stock units vesting through March 8, 2026. |
| 03/08/2024 | Date of grant for 34,461 restricted stock units vesting through March 8, 2027. |
| 03/08/2025 | Date of grant for 85,490 restricted stock units vesting through March 8, 2028. |
| 03/12/2025 | Date of transaction: Kevin Sayer sold 32,498 shares at $70.3801. |
| 03/14/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.